TC
Highly rated in
21
conditions

Dr. Toni K. Choueiri

Dana Farber Cancer Institute
Boston, MA
Highly rated in
21
conditions
Specialties:Oncology
Experience:23 Years
Clinical Trials:Currently Recruiting for 6 Trials
Accepts:New PatientsMedicare
Highly rated in
21
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Toni K. Choueiri's experience treating your condition:
About Dr. Toni K. Choueiri

Toni Choueiri is an Oncologist in Boston, Massachusetts. Choueiri has been practicing medicine for over 23 years and is highly rated in 21 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Urothelial Cancer, Orchiectomy, and Prostatectomy. He is licensed to treat patients in Massachusetts. Choueiri is currently accepting new patients.

His clinical research consists of co-authoring 684 peer reviewed articles and participating in 18 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Toni K. Choueiri it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Toni K. Choueiri accepts the following insurance:

  •  Ambetter
  •  Anthem
Call to see if your plan is accepted.
Locations
450 Brookline Ave, Boston, MA 02215
Background & Education
Graduate Institution
Other, 2000
Specialties
Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Winchester Hospital
Brigham And Womens Hospital
Dana Farber Cancer Institute
Languages Spoken
English
Arabic
Cree
French
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials
A Phase I/IB Trial of Abemaciclib Alone or in Combination With MK-6482 in Advanced Renal Cell Carcinoma
Enrollment Status: Recruiting
Publish Date: December 15, 2022
Intervention Type: Drug
Study Drugs: AbemaciclibMK-6482
Study Phase: Phase 1
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Recruiting
Publish Date: December 15, 2022
Intervention Type: Other, Drug, Biological
Study Drugs: CabozantinibIpilimumabNivolumab
Study Phase: Phase 3
A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (SAMETA)
Enrollment Status: Recruiting
Publish Date: November 22, 2022
Intervention Type: Drug
Study Drugs: SavolitinibDurvalumabSunitinib
Study Phase: Phase 3
A Phase 1/2, Open Label Dose-escalation and Expansion Trial of NKT2152, an Orally Administered HIF2α Inhibitor, to Investigate Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity in Patients With Advanced Clear Cell Renal Cell Carcinoma
Enrollment Status: Recruiting
Publish Date: October 19, 2022
Intervention Type: Drug
Study Drug: Oral NKT2152
Study Phase: Phase 1/Phase 2
A Phase 1/1b Study of SRF388 in Patients With Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: August 18, 2022
Intervention Type: Drug
Study Drug: SRF388
Study Phase: Phase 1
A Phase I Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma
Enrollment Status: Recruiting
Publish Date: March 24, 2022
Intervention Type: Drug
Study Drugs: NeoVaxIpilimumab
Study Phase: Phase 1
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Enrollment Status: Active, not recruiting
Publish Date: November 14, 2022
Intervention Type: Drug
Study Drugs: SavolitinibSunitinib
Study Phase: Phase 3
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS
Enrollment Status: Active, not recruiting
Publish Date: August 03, 2022
Intervention Type: Drug
Study Drugs: CPI-006 Anti-CD73 AntibodyCiforadenantPembrolizumab
Study Phase: Phase 1
Phase II Study of Optimized Management of NIVOlumab Based on REsponse in Patients With Advanced Renal Cell Carcinoma (OMNIVORE Study)
Enrollment Status: Active, not recruiting
Publish Date: May 11, 2022
Intervention Type: Drug
Study Drugs: IpilimumabNivolumab
Study Phase: Phase 2
Phase II Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
Enrollment Status: Active, not recruiting
Publish Date: April 12, 2022
Intervention Type: Drug
Study Drugs: BevacizumabAtezolizumab
Study Phase: Phase 2
Randomized Phase II Study Comparing Cabozantinib (NSC #761968) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma
Enrollment Status: Completed
Publish Date: February 11, 2021
Intervention Type: Drug, Other
Study Phase: Phase 2
Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC
Enrollment Status: Completed
Publish Date: September 18, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Trial of Neoadjuvant Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
Enrollment Status: Completed
Publish Date: October 24, 2016
Intervention Type: Drug
Study Phase: Phase 2
A Phase I Study of Bevacizumab and Escalation Doses of BKM-120 in Patients With Metastatic Renal Cell Carcinoma Who Failed Prior Systemic Therapies
Enrollment Status: Completed
Publish Date: September 21, 2016
Intervention Type: Drug
Study Phase: Phase 1
A Biomarker Study of STA9090 in Castration-Resistant Prostate Cancer (CRPC) With Assessment of Androgen Receptor Pathway Signaling
Enrollment Status: Withdrawn
Publish Date: September 01, 2015
Intervention Type: Drug
Study Phase: Phase 2
A Phase II and Biomarker Study of Tivozanib With Gemcitabine Addition Upon Progression in Patients With Metastatic Refractory Renal Cell Carcinoma
Enrollment Status: Withdrawn
Publish Date: June 19, 2013
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials -
685 Total Publications
Understanding Hospital-Level Patterns of Nonoperative Management for Low-risk Thyroid and Kidney Cancer.
Journal: JAMA network open
Published: November 15, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
DD
Daniel J. Deangelo
Dr. Daniel J. Deangelo
Oncology | Hematology Oncology
Highly rated in
38
conditions
Oncology
Hematology Oncology

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 

Daniel Deangelo is an Oncologist and a Hematologist Oncology expert in Boston, Massachusetts. Deangelo has been practicing medicine for over 30 years and is highly rated in 38 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Systemic Mastocytosis, Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Massachusetts. Deangelo is currently accepting new patients.

MD
Dr. Matthew S. Davids
Oncology | Hematology Oncology
Highly rated in
26
conditions
Oncology
Hematology Oncology

Dana-Farber Cancer Institute, Medical Oncology

450 Brookline Ave, 
Boston, MA 

Matthew Davids is an Oncologist and a Hematologist Oncology expert in Boston, Massachusetts. Davids has been practicing medicine for over 18 years and is highly rated in 26 conditions, according to our data. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Massachusetts. Davids is currently accepting new patients.

EC
Dr. Edwin Choy
Oncology | Hematology Oncology
Highly rated in
34
conditions
Oncology
Hematology Oncology

Mass General Brigham

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 2.7 mi

Edwin Choy is an Oncologist and a Hematologist Oncology expert in Boston, Massachusetts. Choy has been practicing medicine for over 23 years and is highly rated in 34 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Osteosarcoma, Liposarcoma, Bone Tumor, and Bone Marrow Aspiration. He is licensed to treat patients in Massachusetts. Choy is currently accepting new patients.